AstraZeneca Shares Phase 2b Elecoglipron Data

Elecoglipron is an oral once-daily small-molecule GLP-1 receptor agonist currently in clinical development.

A once-daily pill could soon offer a convenient alternative to injectable weight-loss drugs. At the June 2026 American Diabetes Association (ADA) Scientific Sessions, AstraZeneca revealed promising Phase 2b data for elecoglipron (AZD5004), an experimental oral GLP-1 receptor agonist—a type of drug that mimics natural gut hormones to lower blood sugar and curb appetite.

Published in The Lancet, these results show that this daily pill helps patients achieve significant weight loss and blood sugar control. The clinical program evaluated the drug across two major trials: the VISTA trial for obesity and the SOLSTICE trial for type 2 diabetes. Following these positive outcomes, AstraZeneca plans to launch a global Phase 3 program to bring this needle-free option closer to patients.

What Is Elecoglipron and How Does It Help Patients?

Unlike popular injectable treatments that rely on synthetic peptides, elecoglipron is a small-molecule chemical entity. This means scientists can manufacture the pill using standard chemical processes, which could drastically lower production costs. For patients, this could translate to a much more affordable and accessible metabolic medication down the road.

Once swallowed, elecoglipron binds to and activates GLP-1 receptors in the body, stimulating insulin release, reducing glucagon, and sending fullness signals to the brain. Its unique chemical structure allows the drug to remain active in the bloodstream for a full 24 hours. This sustained action makes once-daily dosing highly effective.

Crucially, patients can take elecoglipron with or without food and water. Existing oral options, like semaglutide tablets, require strict morning routines like fasting and waiting 30 minutes before eating or drinking. If you want to explore existing options, you can review current semaglutide treatment programs or tirzepatide options.

What Did the VISTA Trial Reveal About Weight Loss?

The Phase 2b VISTA trial evaluated how different daily doses of elecoglipron affected 310 adults living with obesity or overweight. All participants had at least one weight-related health issue but did not have type 2 diabetes. Researchers randomized them to take either a placebo or elecoglipron for 36 weeks.

Patients taking the highest 75 mg dose of elecoglipron achieved an impressive average weight reduction of 10.5% in just 26 weeks, compared to only 0.6% in the placebo group. By week 36, weight loss in the 75 mg group reached 11.8%. Because the weight-loss curve did not flatten out, researchers believe patients could lose even more weight with longer treatment.

Additionally, a staggering 88.8% of patients on the 75 mg dose lost at least 5% of their body weight by week 26. This significant weight reduction went hand-in-hand with measurable improvements in blood pressure, waist circumference, and cholesterol levels. These secondary outcomes suggest the pill provides broad cardiovascular benefits alongside weight loss.

How Well Did Elecoglipron Manage Type 2 Diabetes in the SOLSTICE Trial?

Managing both blood sugar and weight is a constant challenge for those with type 2 diabetes. The SOLSTICE trial focused on 404 adults with type 2 diabetes that was not fully controlled by diet, exercise, or metformin. Participants took either varying daily doses of elecoglipron or a placebo for 26 weeks.

The results showed that patients taking the 75 mg dose of elecoglipron experienced a remarkable 1.9% drop in their HbA1c levels, a key marker of long-term blood sugar control. Placebo patients saw a mere 0.2% decrease. Alongside glycemic control, the 75 mg treatment group also lost an average of 7.7% of their body weight.

Most patients in the high-dose group successfully reached the recommended HbA1c target of under 7.0%. Fasting blood sugar levels dropped within the very first weeks of starting treatment. These findings highlight the drug's potential to improve beta-cell function and reverse insulin resistance.

Is Elecoglipron Safe and Easy to Take Daily?

Elecoglipron shows a safety profile consistent with other GLP-1 medications. The most common side effects reported were mild-to-moderate gastrointestinal issues like nausea, diarrhea, vomiting, and constipation. These symptoms peaked during the initial dose-escalation phase and decreased as patients adjusted to the daily pill.

Importantly, serious side effects were very rare, and few patients stopped treatment due to adverse reactions. Researchers observed no harmful changes in liver, kidney, or pancreatic enzyme tests. A slight increase in heart rate occurred, which is a known class effect of GLP-1 therapies, but this did not lead to heart complications.

Because elecoglipron is a small molecule, the gut absorbs it directly without needing complex chemical protectors. This allows patients to take it at any time of day, with or without food. To explore if these metabolic benefits are right for you, you can check if you qualify or view current pricing for existing options.

What Are the Next Steps for the Phase 3 EMBOLD and ELUMINATE Trials?

AstraZeneca is moving quickly to launch its global Phase 3 clinical trials, which will support future regulatory applications. The Phase 3 program includes the EMBOLD trials, focusing on long-term weight management in adults with obesity, and the ELUMINATE trials, evaluating blood sugar control in type 2 diabetes. These trials will enroll thousands of diverse patients worldwide to verify safety and long-term benefits.

Researchers will track weight loss and HbA1c levels, while also measuring effects on heart health, liver fat, and kidney function. These comprehensive outcomes could position elecoglipron as a powerful preventative tool against chronic metabolic diseases. AstraZeneca is also investigating combination therapies that pair the drug with other pipeline agents.

The publication of the Phase 2b data in The Lancet provides strong, peer-reviewed support for this clinical program. As the Phase 3 studies progress, they will gather the evidence required for approval by FDA and international health regulators. This once-daily pill could soon transform options for millions of people seeking metabolic support.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.